RecruitingPhase 2NCT05278715

Modified CV Regimen in Optic Pathway Glioma

Studying Optic pathway glioma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beijing Sanbo Brain Hospital
Intervention: Carboplatin(drug)
Enrollment: 75 target
Eligibility: 21 years · All sexes
Timeline: 2022 – 2025

Study locations (1)

Capital Medical University Sanbo Brain Hospital, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05278715 on ClinicalTrials.gov

Other trials for Optic pathway glioma

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT05733572
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
Benedetto Falsini

See all trials for Optic pathway glioma →

← Back to all trials